Articles
25.02.2025
How are countries implementing the EU HTA Regulati...

EU HTA Regulation goes live: A new era for HTA begins  The much-awaited implementation of the r...

Read more
Articles
10.12.2024
A 2024 update: Is NRDL inclusion in China really t...

The National Healthcare Security Administration (NHSA) of China completed its annual review of the N...

Read more
Articles
17.09.2024
Can Real-World Evidence overcome uncertainty in Ra...

We examine how real-world evidence strategies help address uncertainties in rare disease treatments ...

Read more
Articles
10.09.2024
Strategic approaches to achieving HTA approval for...

Achieving HTA approval for orphan drugs requires strategic planning, early engagement, strong eviden...

Read more
Articles
28.08.2024
How to integrate Market Access strategy with evide...

Introduction What is the secret to a successful drug launch? One crucial factor is establishing a cr...

Read more
Articles
20.08.2024
Adapting to the EU HTA: how to restructure your Ma...

Our latest article discusses key strategies for pharma manufacturers' commercial readiness for EU HT...

Read more
Articles
15.08.2024
The role of Health Technology Assessments (HTA) in...

As the focus on sustainability grows, manufacturers will need to address their products’ environme...

Read more
Articles
18.06.2024
What does it take to secure access to digital heal...

Article originally published 11th August 2022, updated 18th June 2024. Introduction Digital health a...

Read more
Articles
11.06.2024
AI could transform diabetes management to improve ...

Article originally published 17th August 2022, updated 11th June 2024. Introduction Artificial intel...

Read more
Articles
05.06.2024
The impact of AI on drug pricing and reimbursement

Artificial intelligence is set to revolutionise the market access and healthcare landscape, but huma...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.